With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
The drug is currently under review for approval with the FDA, which is expected to make a decision by February 26.
Transcript
There will be multiple presentations on the 2-year outcomes of the DERBY and OAKS trials of pegcetacoplan. What is the importance of this drug for the field?
It's such an exciting time for geographic atrophy. As we all know, geographic atrophy is a huge unmet need, and a drug approval during AMD Awareness Month would be a game changer for very large aging population. GA is a leading cause of blindness worldwide. Again, a huge clinical unmet need. If this happens, and we start developing treatments for this disease, this would constitute the most important advance in ophthalmology in the past decade.
GA affects 1 million individuals in the United States and 5 million worldwide, so a large population will be impacted. It's truly so important to begin to have a treatment for this disease in our clinics to offer our patients.
Based on the number of cases, why is there a disproportionate number of cases in the United States? Is geographic atrophy underrecognized or underdiagnosed globally?
Most likely. Because we haven't had any available treatments to date, I firmly believe that a lot of the dry AMD patients from earlier stages, but also geographic atrophy, are hiding in the comprehensive optometric clinics. There's no reason to refer them for retinal assessments or diagnosis and staging of the disease, because we've had absolutely no approved options for this disease.
As you know, the only interventions we can offer are the AREDS vitamins to slow the progression to the wet form or low-vision therapy for the really impacted patients. But truly no treatments have been approved for an option so far, so, why refer?
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More